Drug Delivery Outsourcing In A World Of Pharma’s Shifting Sands

The contract drug delivery industry is facing disruptive influences from an evolving client base, the increase in biologics manufacturing and specialty pharma needs. In Vivo speaks to Catalent’s vice president of strategy, Cornell Stamoran, about the evolution of the industry and the continuous search for efficiency.

The contract drug delivery market has evolved in line with several different factors: financing, client base, and product innovation. Once a vibrant sub-set of the outsourced offerings to the biopharmaceutical industry, three public companies dominated the space: RP Scherer Corp., Elan Corp. PLC and Alza Corp.

However, as the sector evolved, divergent strategies of the three largest companies changed the face of the contract drug delivery...